CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
by Zacks Equity Research
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
by Zacks Equity Research
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Omnicell Solid on Geographic Expansion Amid Stiff Competition
by Zacks Equity Research
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
by Zacks Equity Research
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.
Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4
by Zacks Equity Research
Thermo Fisher (TMO) gains on growth in all business segments in Q4.
Align Technology (ALGN) Beats on Earnings and Revenues in Q4
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q4.
Stryker (SYK) Q4 Earnings Beat, International Revenues Surge
by Zacks Equity Research
Stryker (SYK) gains from solid segmental contributions in Q4.
Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q1
by Zacks Equity Research
Hill-Rom (HRC) benefits from a solid year-over-year revenue increase on domestic growth in Q1, driven by strong segmental performance.
Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4
by Zacks Equity Research
Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.
CONMED's Buffalo Filter Buyout Likely to be Accretive in 2020
by Zacks Equity Research
CONMED's (CNMD) comprehensive surgical smoke evacuation portfolio lends it a competitive edge in the industry.
Why Is Conmed (CNMD) Down 2.8% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3
by Zacks Equity Research
Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.